Docosahexaenoic Acid
产品说明书
 |
同义名 : | DHA; Cervonic acid; Doconexent; C22:6 (all cis-4,7,10,13,16,19) omega-3 Fatty acid; Docosahexaenoic acid (all cis-4,7,10,13,16,19) |
| CAS号 : | 6217-54-5 | |
| 货号 : | A267106 | |
| 分子式 : | C22H32O2 | |
| 纯度 : | 95% | |
| 分子量 : | 328.49 | |
| MDL号 : | MFCD00065722 | |
| 存储条件： |
Pure form Keep in dark place, inert atmosphere, store in freezer, under -20°C In solvent -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 105 mg/mL(319.65 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO 无水乙醇: 50 mg/mL(152.21 mM)，配合低频超声助溶，注意：无水乙醇开封后，易挥发，也会吸收空气中的水分，导致溶解能力下降，请避免使用开封较久的乙醇 |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Docosahexaenoic acid (DHA) plays a crucial role in the growth and functional development of the brain in infants and is necessary for maintaining normal brain function in adults. Consuming a diet rich in DHA enhances learning abilities and memory[1]. DHA is vital for various stages of brain development, including neural cell proliferation, migration, differentiation, and synaptogenesis. Its multiple double bonds and unique structure confer special membrane properties that facilitate effective cell signaling. Decreased levels of DHA are associated with various developmental disorders such as dyslexia, autism spectrum disorder, attention deficit hyperactivity disorder, and schizophrenia[2]. DHA also is a potent retinoid X receptor (RXR) ligand, triggering robust activation of RXR at low micromolar concentrations, with an EC50 for RXRα activation between 5-10 μM fatty acid[3]. | ||
| 临床研究 | |||||
|---|---|---|---|---|---|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT00924547 | Cystic Fibrosis | Phase 2 | Completed | - | United States, Tennessee ... 展开 >> Vanderbilt University Medical Center Nashville, Tennessee, United States, 37232 收起 << |
| NCT00402389 | Depression De... 展开 >>pression, Postpartum 收起 << | Phase 2 | Completed | - | United States, Arizona ... 展开 >> Women's Mental Health Program; University of Arizona; Department of Psychiatry Tucson, Arizona, United States, 85724 收起 << |
| NCT01777048 | ADHD | Phase 3 | Terminated(Low recruitment num... 展开 >>bers) 收起 << | - | Switzerland ... 展开 >> Universitäre Psychiatrische Kliniken (UPK) Basel Basel, Switzerland, 4058 收起 << |
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
3.04mL 0.61mL 0.30mL |
15.22mL 3.04mL 1.52mL |
30.44mL 6.09mL 3.04mL |
| 参考文献 |
|---|